Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.jenburkt.com | |
Market Cap | 329.30 Cr. | |
Enterprise Value(EV) | 273.62 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 55.40 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 13.47 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.99 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 307.73 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 2.42 | Calculated using Price: 746.15 |
Dividend Yield | 1.93 | Period Ending 2023-03 |
No. of Shares Subscribed | 0.44 Cr. | 4,413,300 Shares |
FaceValue | 10 | |
About Jenburkt Pharmaceuticals Ltd. | ||
Jenburkt Pharmaceuticals Ltd, a venture to diversify into the healthcare and pharmaceutical industry, was formed in 1985 by the Bhuta family; late Hemendra N. Bhuta was the promoter of the company while the Bhuta Group was founded by Nandlal Mulji Bhuta |
1 Day |
|
+1.32% |
1 Week |
|
+3.43% |
1 Month |
|
+7.14% |
3 Month |
|
-16.97% |
6 Month |
|
+18.82% |
1 Year |
|
+13.18% |
2 Year |
|
+24.19% |
5 Year |
|
+51.04% |
10 Year |
|
+614.39% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 31.77 | 29.28 | 28.55 | 29.75 | 28.54 | 18.89 | 18.49 | 20.66 | 20.53 | |
Return on Capital Employed (%) | 42.35 | 40.17 | 39.26 | 41.99 | 36.9 | 25.73 | 23.83 | 26.89 | 26.8 | |
Return on Assets (%) | 18.4 | 18.13 | 20.1 | 22.36 | 21.99 | 14.37 | 14.68 | 16.95 | 17.33 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 33 | 40 | 54 | 61 | 77 | 80 | 98 | 117 | 122 | 130 | |
Non Curr. Liab. | 3 | 4 | 4 | 3 | 0 | 5 | 4 | 4 | 3 | 3 | |
Curr. Liab. | 24 | 14 | 18 | 13 | 25 | 20 | 18 | 21 | 16 | 16 | |
Minority Int. | |||||||||||
Equity & Liab. | 61 | 58 | 76 | 78 | 103 | 104 | 120 | 143 | 141 | 149 | |
Non Curr. Assets | 12 | 13 | 13 | 12 | 13 | 15 | 40 | 67 | 60 | 66 | |
Curr. Assets | 49 | 45 | 64 | 66 | 90 | 90 | 80 | 76 | 81 | 83 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 61 | 58 | 76 | 78 | 103 | 104 | 120 | 143 | 141 | 149 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 85 | 94 | 103 | 115 | 123 | 119 | 109 | 124 | 137 | 138 | |
Other Income | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 5 | 5 | 5 | |
Total Income | 87 | 96 | 106 | 118 | 126 | 123 | 114 | 129 | 142 | 143 | |
Total Expenditure | -70 | -77 | -84 | -91 | -98 | -99 | -89 | -97 | -106 | -108 | |
PBIDT | 17 | 19 | 23 | 27 | 28 | 24 | 24 | 32 | 35 | 36 | |
Interest | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | |
Depreciation | -3 | -2 | -2 | -2 | -1 | -2 | -2 | -2 | -2 | -2 | |
Taxation | -5 | -6 | -7 | -8 | -7 | -6 | -5 | -8 | -8 | -8 | |
Exceptional Items | 0 | 0 | |||||||||
PAT | 10 | 11 | 14 | 17 | 20 | 15 | 17 | 22 | 25 | 24 | |
Adjusted EPS | 21 | 23 | 29 | 38 | 43 | 32 | 36 | 49 | 56 | 55 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 11 | 9 | 8 | 10 | 16 | 13 | 15 | 19 | 9 | 17 | |
Cash Fr. Inv. | 0 | 1 | 0 | -10 | 1 | -11 | -3 | -19 | -1 | 3 | |
Cash Fr. Finan. | -7 | 1 | -5 | 1 | -18 | -2 | -11 | -1 | -6 | -21 | |
Net Change | 5 | 11 | 2 | 1 | -1 | 0 | 1 | 0 | 3 | -1 | |
Cash & Cash Eqvt | 17 | 28 | 30 | 2 | 1 | 1 | 3 | 2 | 5 | 4 |
Thu, 25 Apr 2024
Certificate Under Regulation 40(10) Of SEBI (LODR) Regulations 2015. In compliance with Regulation 40(10) of SEBI (LODR) Regulations 2015 please find attached a certificate signed by a Partner of Nilesh Shah & Associates Practicing Company Secretaries under UDIN: F008063F000233728 for the FY starting from 01.04.2023 to 31.03.2024. |
Wed, 24 Apr 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificate and issuance of letter of Confirmation (Duplicate Share Certificate) in lieu thereof. |
Mon, 15 Apr 2024
Compliance Certificate Under Regulation 7(3) Of The SEBI (LODR) Regulatins 2015 For The FY Ended On 31St March 2024. Compliance Certificate u/r 7(3) of the SEBI (LODR) Regulations 2015 for the FY ended on 31st March 2024. |
Fri, 26 Apr 2024 |
Closing Above Previous High |
High Decrease in 3 Months |
ROC Trending Up |
Closing Near 100 SMA |
Closing Near 50 SMA |